Showing 5341-5350 of 6036 results for "".
- COVID-19 Vaccine Protects Monkeys From New Coronavirus, Chinese Biotech Reportshttps://modernod.com/news/covid-19-vaccine-protects-monkeys-from-new-coronavirus-chinese-biotech-reports/2477646/For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, according to a
- Lancet Neurology Publishes Pivotal Phase 3 Data for Genentech’s Satralizumab for NMOSDhttps://modernod.com/news/lancet-neurology-publishes-pivotal-phase-3-data-for-genentechs-satralizumab-for-nmosd/2477640/Lancet Neurology published full pivotal phase 3 clinical data on investigational medicine satralizumab as a monotherapy for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease that is commonly misdiagnosed as multiple scler
- Regenxbio Announces Additional Positive Long-Term and Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-long-term-and-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2477630/Regenxbio provided additional long-term data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). In the phase 1/2a trial of RGX-314, 42 patients with severe wet AMD requiring frequent anti-vascular endothelial growth factor (anti-VE
- Novartis Acquires Amblyotech, A Provider of Digital Therapy for Treatment of Amblyopiahttps://modernod.com/news/novartis-acquires-amblyotech-a-provider-of-digital-therapy-for-treatment-of-amblyopia/2477623/Novartis announced that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia. It is estimated that amblyopia affec
- NovaBay Pharmaceuticals Signs Agreement to Distribute COVID-19 Antibody Rapid Point-of-Care Test to US Health Care Professionalshttps://modernod.com/news/novabay-pharmaceuticals-signs-agreement-to-distribute-covid-19-antibody-rapid-point-of-care-test-to-u-s-healthcare-professionals/2477616/NovaBay Pharmaceuticals announced an agreement with Shenzhen Microprofit Biotech to become the exclusive US distributor of a rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19, according to a company news release. The fluoreca
- The Tests That Could Reopen the Country: How They Workhttps://modernod.com/news/the-tests-that-could-reopen-the-country-how-they-work/2477614/After weeks of sheltering in place, Americans are asking how soon we can return to a more normal life outside our homes. Much of the answer might be in a test. The first phase of testing has been about determining who has COVID-19. The next phase will be about who had it – or may
- How Does Coronavirus Kill? Clinicians Trace a Ferocious Rampage Through the Bodyhttps://modernod.com/news/how-does-coronavirus-kill-clinicians-trace-a-ferocious-rampage-through-the-body/2477615/As the number of confirmed cases of COVID-19 surges past 2.2 million globally and deaths surpass 150,000, clinicians and pathologists are struggling to understand the damage wrought by the coronavirus as it tears through the body. They are realizing that although the lungs are ground zero, its re
- AAO Releases Statement Addressing the Reopening of Ophthalmology Carehttps://modernod.com/news/aao-releases-statement-regarding-returning-to-ophthalmology-practice/2477611/In a letter to its membership, American Academy of Ophthalmology (AAO) CEO David W. Parke II, MD, stated that now is the time to consider the process of reopening ophthalmology care—on a local
- Haag-Streit Group Acquires Majority Stake in VRmagichttps://modernod.com/news/haag-streit-group-acquires-majority-stake-in-vrmagic/2477610/In an effort to expand medical training for ophthalmologists, Haag-Streit announced that it has acquired a majority stake in VRmagic. VRmagic was established in 2001 and is a pioneer for virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit
- FDA Grants Priority Review Approval For Regeneron’s REGN-EB3 to Treat Ebolahttps://modernod.com/news/fda-crants-for-priority-review-approval-for-regenerons-regn-eb3-to-treat-ebola/2477599/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review a new biologics license application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection. The target action date for the FDA decision is October 25, 2020.